Page 14 - Flipbook
P. 14
Neo/adjuvant Nivo: No Difference in RFS
• DSMC stopped trial for inefficacy
• Median Follow-up = 16months
• From abstract: “OS was not mature at the HR: 0.97 [95% CI: 0.74 – 1.28]
time of analysis but was not statistically One-sided P-value: 0.43
different between study arms (HR: 1.48;
95% CI: [0.89 – 2.48]; P1-sided = 0.93)”
Mohamad E. Allaf, MD Content of this presentation is copyright and responsibility of the author. Permission is required for re-use.
Allaf et al. ESMO 2022
